TetraLogic Pharmaceuticals Corporation reported un-audited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $4,322,152 compared to $9,575,719, net loss attributable to common stockholders of $6,828,746 or $4.34 per diluted share compared to $9,330,118 or $0.42 per diluted share, adjusted net loss of $4,243,062 or $2.69 per diluted share compared to $8,647,144 or $0.39 per diluted share for the last year.

For the nine months, the company reported loss from operations of $10,586,233 compared to $23,993,854, net loss attributable to common stockholders of $15,862,081 or $12.41 per diluted share compared to $24,018,623 or $1.10 per diluted share, adjusted net loss of $11,414,475 or $8.93 per diluted share compared to $20,556,362 or $0.94 per diluted share for the last year.